Pitfalls associated with the therapeutic reference pricing practice of asthma medication

Zoltan Kalo\textsuperscript{1,2,5}, Zsolt Abonyi-Toth\textsuperscript{3}, Zoltan Bartfai\textsuperscript{4} and Zoltan Voko\textsuperscript{1,2}

Abstract

Background: Therapeutic reference pricing (TRP) based on the WHO daily defined dose (DDD) is a method frequently employed for the cost-containment of pharmaceuticals. Our objective was to compare average drug use in the real world with DDD and to evaluate whether TRP based on DDD could result in cost savings on maintenance medication and the total direct health expenditures for asthma patients treated with Symbicort Turbuhaler (SYT) and Seretide Diskus (SED) in Hungary.

Methods: Real-world data were derived from the Hungarian National Health Insurance Fund database. Average doses and costs were compared between the high-dose and medium-dose SYT and SED groups. Multiple linear regressions were employed to adjust the data for differences in the gender and age distribution of patients.

Results: 27,779 patients with asthma were included in the analysis. Average drug use was lower than DDD in all groups, 1.38-1.95 inhalations in both SED groups, 1.28-1.97 and 1.74-2.49 inhalations in the medium and high-dose SYT groups, respectively. Although the cost of SED based on the DDD would be much lower than the cost of SYT in the medium-dose groups, no difference was found in the actual cost of the maintenance therapy. No significant differences were found between the groups in terms of total medical costs.

Conclusions: Cost-containment initiatives by payers may influence clinical decisions. TRP for inhalation asthma drugs raises special concern, because of differences in the therapeutic profile of pharmaceuticals and the lack of proven financial benefits after exclusion of the effect of generic price erosion. Our findings indicate that the presented TRP approach of asthma medications based on the daily therapeutic costs according to the WHO DDD does not result in reduced public healthcare spending in Hungary. Further analysis is required to show whether TRP generates additional expenditures by inducing switching costs and reducing patient compliance. Potential confounding factors may limit the generalisability of our conclusions.

Background

The question of what proportion of total healthcare costs should be financed from public resources and what proportion should be spent on pharmaceuticals is under continuous debate in Hungary [1]. Before 2006, the proportion of the total drug cost financed from public resources was larger than the average for OECD countries. Furthermore, between 2000 and 2006, the increase in public pharmaceutical expenditures exceeded the annual rate of 17%. Therefore, the Hungarian National Health Insurance Fund (NHIF) applied a series of cost-containment measures to limit the growth rate of pharmaceutical spending [2,3].

One element of these measures was the extension of the therapeutic reference pricing (TRP) system, also known as the system of therapeutic reference classes. The method implies that the actual reimbursement for the drugs included in the same class (e.g., ATC class with four or five digits) is maximised in line with the average price of products, with the lowest daily therapeutic costs included in that class. The payer indirectly influences the drug price by defining the maximum reimbursement according to the preferred price, and manufacturers can reduce the price of non-referenced products to avoid high copayment. The group of referenced products with

\textsuperscript{5} Correspondence: kalo@tatkelektu
\textsuperscript{1}Department of Health Policy and Health Economics, Institute of Economics, Faculty of Social Sciences, Eötvös Loránd University, Budapest, Hungary
\textsuperscript{2}Syreon Research Institute, Budapest, Hungary
\textsuperscript{3}Full list of author information is available at the end of the article

© 2012 Kalo et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
the lowest daily therapeutic costs should reach a proportion of 50% in the whole class, measured by the number of days of treatment (DOT).

Several technical objections may be raised against the implementation of the TRP system [4]. First, when including drugs that contain different active ingredients in the same reference class, decision-makers usually fail to take into account significant differences in the indications of the drugs, despite their similar mechanisms of action. Second, even if the indications of drugs in a TRP group are the same, there may still be some differences in their efficacy, tolerability and adverse event profiles in the entire patient population or in a subgroup of patients. Because different substances in the same class can be metabolised in different ways, they may show different drug interaction profiles. In such cases, the optimal therapy for a certain group of patients may differ from the medication that is appropriate for most other patients. TRP for inhalation drugs raises special concern because, despite the identical route of administration, the different characteristics of the inhalation devices may lead to differences in efficacy (e.g. lung deposition). Finally, the establishment of therapeutically equivalent daily doses can be difficult in the case of TRP because comparisons can be made only according to the principles of evidence-based medicine based on direct comparative studies. Instead of this, the WHO DDD (average defined daily dose) is used as the basis for the equivalent dose by payers. Even the WHO, however, objects to the use of DDD in decision-making regarding efficacy, pricing and reimbursement [5].

Although concerns have been raised about the use of TRP from the perspective of drug innovation and industrial policy, these are usually offset by financial aspects because the widespread use of reference pricing can lead to massive savings in the pharmaceutical budget [6] [7]. The impact of TRP is often mixed with savings from generic reference pricing (GRP), so it is difficult to determine how much of the saving from reference pricing is attributable to the increased utilisation of generics and generic price erosion. In some cases, when the impact of TRP is separated from GRP, TRP does not display clear savings in pharmaceutical expenditures [8].

The aim of our study was to evaluate the effects of TRP in the case of drugs used in the treatment of asthma. High-dose Seretide Diskus and Symbicort® Turbuhaler® with maximum reimbursement rates of 90% had already been reimbursed by the TRP system within the R03AK06 ATC group. During the period of the analysis no other original or generic products were included in this TRP group. The inclusion of the medium-dose products in this pricing system seems to be the next feasible step. In the high-dose class, TRP ensured an advantageous position for the Symbicort Turbuhaler on the basis of the WHO DDD because the price of a daily dose is 3.7% lower than the price of Seretide Diskus. TRP for a medium dose would make the Seretide Diskus the reference product because the price of a daily dose is 21.2% to 24.1% lower than the price of the two packaged forms of Symbicort.

There are several differences, however, between Sere-tide Diskus and Symbicort Turbuhaler regarding the indications for and the effects of the drugs. Symbicort Turbuhaler can also be used as maintenance and reliever therapy, unlike Seretide Diskus, which is appropriate only for maintenance therapy. This difference results from formoterol, the beta-agonist component of Symbicort. Unlike salmeterol, formoterol not only has a long-term effect but also a rapid bronchodilating effect [9]. Formoterol reaches its effect in three to four minutes, similarly to the widely-used reliever salbutamol [10].

Compared with salmeterol, formoterol has a possible advantage in its dose-dependent bronchoprotective effects on methacholine-induced bronchoconstriction [11]. The maximum daily dose of formoterol in the treatment of asthma is eight inhalations, or 36 mcg; however, for temporary regiments of a few days, 12 inhalations, or 54 mcg, are also allowed. The same cannot be said for salmeterol because its maximum daily dose is 100 mcg or 2x1 inhalation for all dosage forms of this product. This is because of the narrow therapeutic window, the systemic effects that appear above the maximal dose and the lack of further smooth muscle-relaxing effects above the maximal dose [12,13].

Taking into account the WHO DDD, it can be expected that the price of Symbicort Turbuhaler for patients on chronic therapy will be lower for the high-dose form and higher for the medium dose when compared with Seretide Diskus. Due to the rapid bronchodilating effects of Symbicort, the use of other relievers is expected to be lower in patients using Symbicort Turbuhaler than in those treated with Seretide Diskus.

Due to its wide therapeutic window and rapid reliever effects, formoterol allows for acute needs-based administration (see the SMART indication for Symbicort), which may reduce the number of exacerbations if the steroid component is administered at the appropriate time. Furthermore, the narrower therapeutic window of salmeterol could lead to a higher incidence of adverse events in patients exceeding the upper limit of the therapeutic window.

In our study we evaluated whether in the real world there was a difference in the costs of maintenance medication, attack-reliever therapies, treatment of exacerbations and total direct health expenditures between patients treated with Symbicort Turbuhaler and Seretide Diskus. We used real-world cost data from the NHIF for analysis.
Methods
For the selection of patients, we used real-world outpatient care, inpatient care and drug utilisation databases (data on prescriptions filled in pharmacies) of the NHIF. IRB approval was not necessary for the retrospective analysis of aggregated patient records.

We included adult patients who were born before 1990, had filled a medium- or high-dose prescription of Symbicort (SYT) or Seretide Diskus (SED) in the first two months of 2008, and had filled a SYT or SED prescription at least twice in 2008 with 90% reimbursement of NHIF with an asthma ICD10 code (J45, J96). We excluded patients who filled prescriptions for both study drugs (i.e. those who were mixing SYT and SED or those who also used Seretide Evohaler) and those who filled different dosage forms in 2008 (Table 1).

The National Health Insurance Fund provided us with data on the mean annual costs for 2008 for the following cost items by age group (18–30, 31–40, 41–50, 51–60, 61–70, >70 years), gender, maintenance drug type (SYT or SED) and dosage form (medium or high dose):

1. units and public prices of maintenance antiasthmatic pharmaceutical therapies (SYT or SED),
2. units and public prices of reliever medications (drugs containing salbutamol, terbutaline or fenoterol),
3. units and public prices of medications used for exacerbation (containing ampicillin, amoxicillin, penicillin, tetracycline, trimetoprim and sulfamethoxazole, cefuroxime, cefamandol, cefaclor, cefprozil, cefotaxim, ceftazidim, ceftriaxon, cefixim, cefoperazone, cefituben, azithromycin, clarithromycin, roxithromycin, ofloxacin, ciprofloxacin, levofloxacinc, moxifloxacinc, or methylprednisolone).
4. public prices of all filled prescription drugs,
5. reimbursement for outpatient care required for asthma (the ICD code of the disease justifying the care being J45 or J96),
6. reimbursement for all outpatient care,
7. reimbursement for inpatient care required for asthma (the ICD code of the disease justifying the care being J45 or J96),
8. reimbursement for all inpatient care.

We converted Hungarian forints into US dollars by employing the 2009 GDP PPP exchange rate published by the OECD (1 USD = 135 HUF).

We calculated the average daily inhalations of the maintenance drugs by dividing the total quantity of prescribed medications filled without the last prescription over the number of days between the first and last first prescriptions filled.

We did not receive data for the other comorbidities of the patients and assumed that there were no differences between the patient groups in this respect.

In the descriptive statistical analysis, we compared the inpatient costs, the outpatient costs, the costs of the maintenance medications, costs of the drugs used for exacerbation, costs of the reliever therapies and all other medication therapies, and the total costs in all four groups (high-dose SYT, medium-dose SYT, high-dose SED and medium-dose SED).

Next, we used multiple linear regressions to adjust the data for the differences in gender and age distribution of the patients receiving different maintenance treatments. Because only aggregate data were available, it was not possible to use linear regressions based on the traditional least-square method. Instead, we performed a regression analysis on the aggregated data using the metareg program of the STATA10 statistical program package [14]. This analysis can be considered as a way of standardising the mean differences in costs for both age and gender.

Results
We analysed the data from a total of 27,799 asthma patients; 12,260 used Seretide Diskus, and 15,539 used Symbicort Turbuhaler. Table 2 shows the distribution of the study population according to age, gender and maintenance therapy. The proportion of the patients over 60 years of age was a few percentage points higher in all study groups among Seretide users than among Symbicort users.

Average drug use was lower in both groups than the WHO DDD, which consists of two daily inhalations for the medium and high doses of Seretide but two daily inhalations for the high dose and four daily inhalations for the medium dose of Symbicort. In the Seretide

Table 1 Classification of study drugs according to strength

| Name                        | Package form | Number of days of treatment | Strength | DTC  |
|-----------------------------|--------------|-----------------------------|----------|------|
| Symbicort Forte Turbuhaler  | 1 × 60 doses | 30                          | high dose| 3.35 |
| Seretide Diskus 50/500      | 1 × 60 doses | 30                          | high dose| 3.48 |
| Symbicort Turbuhaler        | 1 × 60 doses | 15                          | medium dose| 3.57 |
| Symbicort Turbuhaler        | 1 × 120 doses| 30                          | medium dose| 3.35 |
| Seretide Diskus 50/250      | 1 × 60 doses | 30                          | medium dose| 2.64 |

DTC: daily therapeutic costs based on the WHO DDD (USD).
Table 2 Distribution of the study population by age group, gender, maintenance therapy and strength of therapy

| Age group (year) | Male | | | Female | | | Female |
|-----------------|------|------|------|------|------|------|------|------|
|                 | Seretide | Symbicort | Seretide | Symbicort | Seretide | Symbicort | Seretide | Symbicort |
|-----------------|--------|----------|--------|----------|--------|----------|--------|----------|
| 18-30           | 93 (3.7%) | 125 (7.6%) | 100 (3.0%) | 79 (3.5%) | 364 (16.4%) | 728 (16.5%) | 321 (7.7%) | 703 (9.7%) |
| 31-40           | 176 (7.0%) | 188 (11.4%) | 195 (5.8%) | 183 (8.2%) | 295 (13.3%) | 753 (17.1%) | 355 (8.5%) | 804 (11.1%) |
| 41-50           | 249 (9.9%) | 210 (12.8%) | 424 (12.0%) | 336 (15.0%) | 305 (13.8%) | 627 (14.2%) | 556 (13.3%) | 1 106 (15.3%) |
| 51-60           | 654 (26.1%) | 382 (23.2%) | 1 008 (30.0%) | 685 (30.6%) | 451 (20.3%) | 878 (19.9%) | 1 100 (26.4%) | 1 956 (27.0%) |
| 61-70           | 679 (27.1%) | 416 (25.3%) | 842 (25.0%) | 522 (23.3%) | 423 (19.1%) | 797 (18.1%) | 954 (22.9%) | 1 528 (21.1%) |
| 71-X            | 654 (26.1%) | 326 (19.8%) | 795 (23.6%) | 436 (19.5%) | 380 (17.1%) | 622 (14.1%) | 887 (21.3%) | 1 149 (15.9%) |
| Total           | 2 505 (100%) | 1 647 (100%) | 3 364 (100%) | 2 241 (100%) | 2 218 (100%) | 4 405 (100%) | 4 173 (100%) | 7 246 (100%) |

Numbers are patient numbers (% column).

Table 3 Average daily inhalation of Symbicort Turbuhaler and Seretide Diskus in patients with asthma

| Age (years) | Male | | | Female | | | Female |
|-------------|------|------|------|--------|------|------|------|
|              | Seretide | Symbicort | Seretide | Symbicort | Seretide | Symbicort | Seretide | Symbicort |
|-----------------|--------|----------|--------|----------|--------|----------|--------|----------|
| 18-30           | 1.38 | 1.28 | 1.36 | 1.19 | 1.30 | 1.90 | 1.95 | 1.74 |
| 31-40           | 1.34 | 1.97 | 1.28 | 1.47 | 1.36 | 1.97 | 1.32 | 1.78 |
| 41-50           | 1.61 | 1.62 | 1.34 | 1.48 | 1.33 | 2.07 | 1.36 | 2.03 |
| 51-60           | 1.46 | 1.66 | 1.37 | 1.56 | 1.39 | 2.40 | 1.33 | 2.22 |
| 61-70           | 1.51 | 1.87 | 1.47 | 1.67 | 1.44 | 2.38 | 1.42 | 2.27 |
| >70            | 1.50 | 1.67 | 1.42 | 1.73 | 1.48 | 2.49 | 1.43 | 2.31 |
therapy cost according to the WHO DDD, our analysis provides evidence for the limitations of this method in asthma. No relationship was found between the daily therapeutic costs calculated by means of the NHIF methodology and the real-world costs of actual drug use. Therefore, in our presented case the expected lower daily therapeutic costs did not exist in practice.

Our analysis also showed that therapeutic referencing based solely on the daily therapeutic costs in the R03AK06 group did not lead to a reduction of expenditure for the payer. TRP might even generate additional expenditures, as in addition to the costs calculated in this analysis, costs related to a switch to another treatment should also be taken into account. When patients change inhalation devices, they need to learn how to use the new device. Moreover, switching to a new inhalation device may reduce compliance due to the individual preferences of the patients, which may eventually lead to decreased effectiveness [17,18].

In interpreting the results, it should be taken into account that Seretide doses can only be increased by switching from the medium dose to the high dose; consequently, these cases were excluded from this study. The doses for Symbicort, on the other hand, can be adjusted in a different way because a daily dose of 2x1 inhalations can be increased to 2x2 inhalations. Therefore, an appropriate comparison for some of the patients using a medium dose of Symbicort would have been high-dose Seretide, which is also supported by the fact that daily inhalations of the medium dose of Symbicort were relatively high compared with the medium dose of Seretide. The higher daily inhalations of Symbicort may also be explained by the Symbicort SMART® indication. Although an analysis that took into account this dose increase could have been performed on individual patient data, we only had access to aggregated administrative financing data in this study.

Nevertheless, although this analysis followed a conservative approach with regard to Symbicort, NHIF still could not expect any real-world savings by referencing the WHO DDD.

This study also shows that administrative financial data support the clinical data, which suggest a decreased need for relievers and exacerbation treatments if patients are treated with Symbicort. This proves that differences in the indications cannot be disregarded during the process of referencing and that different indications should not be treated in the same way.

---

### Table 4 Average annual healthcare costs of asthma patients receiving medium- or high-dose Symbicort or Seretide Diskus therapy (USD)

| Group   | Treatment | Number of patients | Expenditure (USD) |
|---------|-----------|--------------------|-------------------|
|         |           | Maintenance therapy | Reliever medication | Exacerbation medication | Total medication | Special* medication | Total outpatient care | Special† inpatient care | Total inpatient care | Total†* |
| High dose | Symbicort | 3 888 | 851.7 | 17.8 | 65.9 | 1240.2 | 42.7 | 220.1 | 59.2 | 760.2 | 3120.6 |
|         | Seretide  | 5 869 | 796.9 | 21.3 | 77.9 | 2540.3 | 43.1 | 228.6 | 75.2 | 786.6 | 3555.6 |
| raw difference (Sym vs Ser) | | | −15.0 | −14.4 | −3.5 | −116.1 | −1.4 | −5.5 | −2.0 | −5.6 | −52.0 |
| adjusted difference | | | 53.3 | −3.7 | −12.0 | 400.1 | −0.4 | −8.5 | −16.0 | −26.4 | −43.0 |
| 95% CI of the adjusted difference | | | 25.1; 81.6 | −5.3; −20.0 | −23.3; −8.5 | −242.3; −9.2 | −3.0; 1.9 | −29.6; 11.3 | −33.6; 5.4 | −140.9; 118.1 | −628.3; 166.5 |
| p-value | | | 0.001 | <10⁻³ | <10⁻³ | 0.04 | 0.7 | 0.4 | 0.1 | 0.9 | 0.2 |
| Medium dose | Symbicort | 11 651 | 575.8 | 11.6 | 43.3 | 1563.0 | 40.2 | 208.2 | 43.1 | 510.0 | 2281.2 |
|         | Seretide  | 6 391 | 575.3 | 13.5 | 40.5 | 1590.5 | 38.9 | 211.2 | 30.0 | 494.4 | 2296.1 |
| raw difference (Sym vs Ser) | | | −0.6 | −1.9 | 2.7 | −27.5 | 1.3 | −3.0 | 13.1 | 15.6 | −14.9 |
| adjusted difference | | | 0.6 | −2.2 | 3.4 | 9.0 | 1.7 | 3.8 | 14.2 | 34.9 | 93.1 |
| 95% CI of the adjusted difference | | | −20.0; 21.2 | −4.0; −0.5 | −0.8; 7.6 | −68.7; 86.6 | 0.2; 3.14 | −12.3; 19.9 | 3.9; 24.4 | −18.6; 88.3 | −87.9; 274.15 |
| p-value | | | 0.96 | 0.02 | 0.1 | 0.8 | 0.03 | 0.6 | 0.01 | 0.2 | 0.3 |

CI: confidence interval.

* ICD code of the diagnosis justifying care is J45 or J96.
† the ICD code on which the main diagnosis is based or that for the main diagnosis justifying the care is J45 or J96.
‡ total costs of drugs, both outpatient and inpatient care.
§ adjusted for age and gender.
Our study has several limitations. Although the inclusion criteria guarantee that SYT and SED were prescribed for patients with asthma indication and not COPD, coding errors could not be excluded due to the retrospective nature of our analysis.

Medications for exacerbations could also be prescribed for non-asthma-related events. Similarly, outpatient and inpatient episodes could also be related to other comorbidities, so conclusions related to these outcomes have limited generalisability.

Confounding factors may bias our results. Theoretically, the different characteristics between the two study groups may partially explain the differences in costs. The effects of confounding could have been controlled by a multiple regression analysis. For such analyses, however, individual patient data would be required. According to the NHIF, however, such data could not be released for research purposes, not even in an anonymous form. Nevertheless, we used an adjustment method based on the aggregated data to control for age and gender.

Conclusion
Cost-containment initiatives by payers may influence clinical decisions. TRP for inhalation asthma drugs raises special concern, because of differences in the therapeutic profile of pharmaceuticals and the lack of proven financial benefits after exclusion of the effect of generic price erosion. Our findings indicate that the presented TRP approach of asthma medications based on the daily therapeutic costs according to the WHO DDD does not result in reduced public healthcare spending in Hungary.

Further analysis is required to show whether TRP generates additional expenditures by inducing switching costs and reducing patient compliance. Potential confounding factors may limit the generalisability of our conclusions.

Acknowledgements
This study was financially supported by AstraZeneca Hungary. Authors gratefully acknowledge their support. AstraZeneca Hungary had no influence on the review process, was not involved in writing the manuscript. Authors summarized their independent professional opinion and take full responsibility for potential errors in the manuscript. The manuscript was edited for proper English language, grammar, punctuation, spelling, and overall style by qualified native English speaking editors at American Journal Experts (support@journalexperts.com).

Author details
1Department of Health Policy and Health Economics, Institute of Economics, Faculty of Social Sciences, Eötvös Loránd University, Budapest, Hungary. 2Syreon Research Institute, Budapest, Hungary. 3RXP Ltd, Budapest, Hungary. 4Elisabeth Teaching Hospital Sopron, Department of Pulmonology, Sopron, Hungary. 5Health Economics Research Centre, Institute of Economics, Faculty of Social Sciences, Eötvös Loránd University, Pázmány Péter setány 1/a, Budapest H-1117, Hungary.

Received: 26 February 2011 Accepted: 28 June 2012
Published: 20 July 2012

References
1. Inotai A, Merész G, Kaló Z: Assessment of the pharmaceutical expenditure in Hungary. [in Hungarian]. Acta Pharm Hung 2010, 80(4):162–172.
2. Pharmaceutical Pricing and Reimbursement Information. HUNGARY: June 2007. http://ppr.oebgov.at/Downloads/Results/Hungary__PPR_2007.pdf.
3. Tei P, Groot W: Cost containment measures for pharmaceuticals expenditure in the EU countries: a comparative analysis. The Open Health Services and Policy Journal 2009, 2:71–83.
4. Kaló Z, Vincez Z, Lovas K, Bodrogi J. Reference pricing system as a potential method of pharmaceutical cost-containment [in Hungarian]. Gyógyszereset 2003, 47:139–146.
5. WHO Collaborating Centre for Drug Statistics Methodology: Norwegian Institute of Public Health. The actual version if this reference can be downloaded from; http://www.whocc.no/atc_ddd_publications/guidelines/.
6. Ubeda A, Cardo E, Sellés N, Broseta R, Trillo JL, Fernández-Llimós F: Antidepressant utilization in primary care in a Spanish region: impact of generic and reference-based pricing policy (2000–2004). Soc Psychiatry Psychiatr Epidemiol 2007, 42(3):181–188.
7. Stargardt T: The impact of reference pricing on switching behaviour and healthcare utilisation: the case of statins in Germany. Eur J Health Econ 2010, 11(3):267–277.
8. Kaló Z, Muszbek N, Bodrogi J, Bóldi J: Does therapeutic reference pricing always result in cost-containment? The Hungarian evidence. Health Policy 2007, 80:402–412.
9. Lindberg A, Szalai Z, Pulletets T, Radecky E: Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction. Resp Res 2007, 12:732–739.
10. Sebérová E, Andersson A: Oxis (formoterol given by Turbuhaler) showed as rapid an onset of action as salbutamol given by a pMDI. Respir Med 2000, 94:607–611.
11. Palmqvist M, Ibksen T, Mellen A, Lütvall J: Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. AJRCCM 1999, 160:244–249.
12. Bennett JA, Tattersfield AE: Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjects. Thorax 1997, 52:458–464.
13. Källström BL, Sjöberg J, Waldeck B. The interaction between salmeterol and beta 2-adrenoceptor agonists with higher efficacy on guinea-pig trachea and human bronchus in vitro. Br J Pharmacol 1994, 113:687–696.
14. Sharp S: Meta-analysis regression. Stata Technical Bulletin 1998, 42:16–22.
15. Gremmelsmann T, Himmel W: Discrepancies between prescribed and reimbursed defined daily doses: a matter of patients or drug classes? Eur J Clin Pharmacol 2011, 67:347–354.
16. Duarte-Ramos F, Cabrita J. Using a pharmaco-epidemiological approach to estimate diabetes type 2 prevalence in Portugal. Pharmacoepidemiol Drug Saf 2006, 15:269–274.
17. Wilson DS, Gillon MS, Rees PJ: Use of dry powder inhalers in COPD. Int J Clin Pract 2007, 61:2005–2008.
18. Lavorini F, Magnan A, Dubus JC, Voshaar T, Corbetta L, Broeders M, Dekhuijzen R, Sanchis J, Viejo JL, Barnes P, Corrigan C, Levy M, Crompton GK: Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med 2008, 102:593–604.

doi:10.1186/1471-2466-12-35
Cite this article as: Kalo et al: Pitfalls associated with the therapeutic reference pricing practice of asthma medication. BMC Pulmonary Medicine 2012 12:35.